title: Survival of women with ovarian carcinomas and borderline tumors is not affected by estrogen and progesterone receptor status.
abstract: OBJECTIVE
  To examine the patterns of estrogen receptor (ER) and progesterone receptor (PR) expression in borderline ovarian tumors (BOTs) and ovarian carcinomas. We also assessed the disease-free survival (DFS) and overall survival (OS) in women with ovarian carcinoma, in relation to ER and/or PR expression.
  
  
  METHODS
  We examined ER/PR expression in 38 BOTs and 172 ovarian carcinomas removed from patients treated at the State University of Campinas-UNICAMP (Brazil), from 1993 to 2008 and followed for up to 60 months using tissue microarray-based immunohistochemistry.
  
  
  RESULTS
  Twenty-eight (73.7%) mucinous and 10 (26.3%) serous BOTs were included. Ovarian carcinomas consisted mainly of 79 (46.0%) serous, 44 (25.5%) mucinous, 17 (9.8%) endometrioid, 10 (5.8%) clear-cell types. There was no significant difference of the ER/PR expression between BOT and ovarian carcinoma (p=0.55 for ER alone, 0.90 for PR alone, and 0.12 for combined expression). The level of ER/PR expression in BOTs was significantly higher in serous than in mucinous tumors (p<0.01). In carcinomas, ER/PR was higher in serous tumors than in mucinous (p<0.01) and clear cell tumors (p=0.02), and higher in endometrioid tumors than in mucinous tumors (p<0.01). DFS was affected neither by the clinical characteristics nor by combined steroid receptor status. OS was found to be significantly worse (p<0.01) only in women with stages II-IV tumors and those with residual disease after surgery (p<0.01).
  
  
  CONCLUSIONS
  Overall, serous and endometrioid tumors were predominantly ER/PR positive, whereas mucinous and clear-cell tumors were preponderantly ER/PR negative. DFS and OS were not affected by ER/PR expression.
authors: Department of Obstetrics and Gynecology, Faculty of Medical Sciences, State University of Campinas-UNICAMP, São Paulo, Brazil.
authors: Luis Felipe
authors: LF
authors: Sallum
authors: Luis Otavio
authors: LO
authors: Sarian
authors: Liliana
authors: L
authors: Lucci De Angelo Andrade
authors: José
authors: J
authors: Vassallo
authors: Fernando Augusto
authors: FA
authors: Soares
authors: Glauce Aparecida
authors: GA
authors: Pinto
authors: Patrícia Andréia
authors: PA
authors: Ferreira
authors: Sophie
authors: S
authors: Derchain
keywords: Borderline ovarian tumor; Estrogen receptor; Immunohistochemistry; Ovarian carcinoma; Progesterone receptor; Tissue microarray
references: Am J Clin Oncol. 1998 Oct;21(5):447-51
references: 9781597
references: Gynecol Oncol. 2009 Apr;113(1):99-104
references: 19178934
references: Cancer. 2000 Oct 15;89(8):1783-91
references: 11042574
references: Cancer. 1990 Feb 1;65(3):486-91
references: 2297640
references: Br J Obstet Gynaecol. 1990 Aug;97(8):706-12
references: 2400748
references: Obstet Gynecol. 1990 Aug;76(2):258-63
references: 2371031
references: Gynecol Oncol. 1996 Mar;60(3):424-7
references: 8774651
references: Int J Gynaecol Obstet. 2000 Aug;70(2):209-62
references: 11041682
references: Jpn J Cancer Res. 2002 Jul;93(7):807-15
references: 12149147
references: Oncol Rep. 2007 Nov;18(5):1051-9
references: 17914554
references: Gynecol Oncol. 1989 Jul;34(1):57-60
references: 2737527
references: Gynecol Oncol. 1992 Dec;47(3):317-22
references: 1473744
references: Cancer Res. 1988 Nov 1;48(21):6222-6
references: 3167868
references: Cancer. 1990 Aug 15;66(4):740-4
references: 2386902
references: Gynecol Obstet Invest. 1988;25(2):135-40
references: 3371761
references: Int J Gynecol Cancer. 2009 May;19(4):620-7
references: 19509560
references: Mod Pathol. 2004 Jul;17(7):790-7
references: 15073602
references: Mol Cell Endocrinol. 2004 Jun 30;221(1-2):97-104
references: 15223136
references: Obstet Gynecol. 1986 Dec;68(6):751-8
references: 3785785
references: Gynecol Oncol. 2009 Sep;114(3):480-5
references: 19560192
references: Gynecol Oncol. 1986 Jan;23(1):65-76
references: 3943754
references: Reprod Biol Endocrinol. 2003 Oct 07;1:73
references: 14577831
references: Gynecol Oncol. 2005 Mar;96(3):671-7
references: 15721410